Abstract
The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa. Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azithromycin / pharmacology
-
Ceftazidime / pharmacology
-
Colistin / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Synergism
-
In Vitro Techniques
-
Levofloxacin
-
Meropenem
-
Microbial Sensitivity Tests
-
Mutation / drug effects*
-
Ofloxacin / pharmacology
-
Penicillanic Acid / analogs & derivatives
-
Penicillanic Acid / pharmacology
-
Piperacillin / pharmacology
-
Piperacillin, Tazobactam Drug Combination
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / genetics*
-
Thienamycins / pharmacology
-
Tobramycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Thienamycins
-
Piperacillin, Tazobactam Drug Combination
-
Levofloxacin
-
Azithromycin
-
Penicillanic Acid
-
Ceftazidime
-
Ofloxacin
-
Meropenem
-
Tobramycin
-
Piperacillin
-
Colistin